A Phase 2 interventional study of VK5211 and Placebo in Hip Fractures, sponsored by Viking Therapeutics, Inc.. Completed at 21 sites in 4 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-12-29.
Sponsored by Viking Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 133 studies in Hip Fractures with a site in United States — 22 open to participants now, 31 under way, none of them phase 3. Hip Fractures · United States.
Among the 133 studies in Hip Fractures with a site in United States, this one is the 44th largest by enrollment of the 105 interventional ones that give a count, is one of 10 that started in 2015, is one of 16 in phase 2, and was the 57th registered.
843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.
Browse Hip Fractures studies →22 of the 133 studies in Hip Fractures with a site in United States are open now. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 65+
SI-BONE, Inc. · Sites in United States
Ages 60+
University of Maryland, Baltimore · Sites in United States
Ages 60+
University of Southern California · Sites in United States, Canada, Norway and 2 more countries
Ages 60+
Yale University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
133 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 18 · Phase 3 10 · Phase 4 15
First in 1980; this study’s year is marked. 10 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 108 is above the median of 86 across 534 interventional studies indexed under Hip Fractures.
Median enrollment 64 across the 105 interventional studies, 160 across the 26 observational. Of the 84 that completed or were terminated, 36 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 133 have an industry lead sponsor. The 10 most frequent:
Viking Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; 4 are open to participants now.
Viking Therapeutics, Inc. has 1 study filed under Hip Fractures — fewer than ten, so there is no comparison to draw.
16 of the studies in Hip Fractures with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06407427Yale UniversityEvaluating the Efficacy of a Mobile Application in Postoperative Rehabilitation | 2026-12 |
| NCT04809714University of Alabama at BirminghamThe Role of Blood Flow Restriction Therapy in Postoperative Elderly Patients With Hip Fracture | 2026-12-13 |
| NCT04113044AO Innovation Translation CenterGo Fit Fast, Recovery Trajectory Using PROMIS®, Linking PROMIS® | 2026-12-31 |
| NCT06024304Paul E. MatuszewskiInterTAN: Integrated Dual Screw Design Improve Biomechanics/Function Following Fixation Surgery | 2027-01-01 |
| NCT04937868University of California, Los AngelesDeveloping a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients | 2027-01-15 |
Add all 16 to your calendar (.ics) → With an account.
Among the 133 studies in Hip Fractures with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to investigate the safety, tolerability, and efficacy of VK5211 after 12 weeks of treatment.
Males and females ≥65 years old who are ambulatory and recovering from a hip fracture will be eligible for participation 3-7 weeks post-injury.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo QD
Drug: Placebo
0.5mgQD
Drug: VK5211
1.0mg QD
Drug: VK5211
2.0mg QD
Drug: VK5211
Capsule
Capsule
Efficacy in Hip Fracture Patients Confirmed by DXA Scan.
Efficacy of VK5211 after 12 weeks of treatment by mean placebo-corrected percentage change in total body less head (TBLH) lean body mass assessed by whole body dual-energy x-ray absorptiometry scan (DXA) scan.
Time frame: Baseline and Week12
| Milestone | Placebo | VK5211- 0.5mg | VK5211- 1.0mg | VK5211- 2.0mg |
|---|---|---|---|---|
| Started | 28 | 29 | 26 | 25 |
| Completed | 19 | 22 | 17 | 17 |
| Not completed | 9 | 7 | 9 | 8 |
Efficacy of VK5211 after 12 weeks of treatment by mean placebo-corrected percentage change in total body less head (TBLH) lean body mass assessed by whole body dual-energy x-ray absorptiometry scan (DXA) scan.
| PBO adjusted percent change | Placebo | VK5211- 0.5mg | VK5211- 1.0mg | VK5211- 2.0mg |
|---|---|---|---|---|
| Efficacy in Hip Fracture Patients Confirmed by DXA Scan. | 0 (0 to 0) | 4.75 (1.70 to 7.80) | 7.15 (3.76 to 10.54) | 9.08 (5.55 to 12.60) |
Collected over 24 Weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/28 (0%) | 4/28 (14.3%) | 10/28 (35.7%) |
| VK5211- 0.5mg | 0/29 (0%) | 2/29 (6.9%) | 11/29 (37.9%) |
| VK5211- 1.0mg | 0/26 (0%) | 3/26 (11.5%) | 8/26 (30.8%) |
| VK5211- 2.0mg | 0/25 (0%) | 5/25 (20%) | 16/25 (64%) |
| Event | Placebo | VK5211- 0.5mg | VK5211- 1.0mg | VK5211- 2.0mg |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/28 | 0/29 | 0/26 | 1/25 |
| PneumoniaInfections and infestations | 0/28 | 0/29 | 0/26 | 1/25 |
| Femur FractureInjury, poisoning and procedural complications | 0/28 | 0/29 | 0/26 | 1/25 |
| Cerebrovascular AccidentNervous system disorders | 0/28 | 0/29 | 0/26 | 1/25 |
| Chronic Kidney DiseaseRenal and urinary disorders | 0/28 | 0/29 | 0/26 | 1/25 |
| HaematomaVascular disorders | 0/28 | 0/29 | 0/26 | 1/25 |
| Cardiac FailureCardiac disorders | 0/28 | 0/29 | 1/26 | 0/25 |
| Thyroxine DecreasedInvestigations | 0/28 | 0/29 | 1/26 | 0/25 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 0/28 | 0/29 | 1/26 | 0/25 |
| Hip FractureInjury, poisoning and procedural complications | 1/28 | 0/29 | 0/26 | 0/25 |
| Event | Placebo | VK5211- 0.5mg | VK5211- 1.0mg | VK5211- 2.0mg |
|---|---|---|---|---|
| Hepatic Enzyme IncreasedInvestigations | 1/28 | 1/29 | 1/26 | 4/25 |
| AnaemiaBlood and lymphatic system disorders | 1/28 | 0/29 | 0/26 | 2/25 |
| HeadacheNervous system disorders | 0/28 | 1/29 | 1/26 | 2/25 |
| ContusionInjury, poisoning and procedural complications | 2/28 | 0/29 | 0/26 | 0/25 |
| Cardiac Failure CongestiveCardiac disorders | 0/28 | 0/29 | 0/26 | 1/25 |
| Cardiac Valve DiseaseCardiac disorders | 0/28 | 0/29 | 0/26 | 1/25 |
| DiarrhoeaGastrointestinal disorders | 0/28 | 0/29 | 0/26 | 1/25 |
| Dry MouthGastrointestinal disorders | 1/28 | 0/29 | 1/26 | 1/25 |
| HaematocheziaGastrointestinal disorders | 0/28 | 0/29 | 0/26 | 1/25 |
| NauseaGastrointestinal disorders | 0/28 | 0/29 | 0/26 | 1/25 |
| Age, Continuous(Years) | Placebo | VK5211- 0.5mg | VK5211- 1.0mg | VK5211- 2.0mg | Total |
|---|---|---|---|---|---|
| Median | 76 (64 to 91.7) | 78 (65 to 86) | 78.5 (65 to 94) | 78 (65 to 93.7) | 78 (64 to 94) |
| Sex: Female, Male(Participants) | Placebo | VK5211- 0.5mg | VK5211- 1.0mg | VK5211- 2.0mg | Total |
|---|---|---|---|---|---|
| Female | 19 | 23 | 22 | 19 | 83 |
| Male | 9 | 6 | 4 | 6 | 25 |
| Race (NIH/OMB)(Participants) | Placebo | VK5211- 0.5mg | VK5211- 1.0mg | VK5211- 2.0mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 29 | 24 | 25 | 78 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 1 | 0 | 1 | 0 | 2 |
| White | 27 | 0 | 0 | 0 | 27 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in Nov 2017, 24 months.
Results were first posted in Dec 2025, 8 years 1 month after primary completion. A results delay was requested in Oct 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.